Ozempic is transforming the health of Denmark’s economy
Novo Nordisk’s success shows the outsized effect a single company can have on a nation
Add BT as a preferred source
FROM both a biomedical and economic point of view, the success of the new class of weight-loss drugs is something to behold.
Not only are they a remarkable scientific achievement, they are also – in the case of Ozempic and Wegovy, both made by Novo Nordisk – a huge boon to the Danish economy. The pharmaceutical industry kept Denmark from falling into a recession last year.
The dependence of some mid-sized economies on a single commodity, often related to oil or natural gas, is a familiar story. The new twist, which may become increasingly common, is a national economy dependent on a single company – not a natural resource. This will lead to some fundamentally new economic and political dynamics.
TRENDING NOW
Father-and-son duo Raj Kumar and Kishin in exclusive due diligence to buy Scotts Square
When every phone becomes a satellite phone, what happens to Asia’s telcos?
Koh Brothers Eco Engineering faces up to S$57.6 million in potential legal liabilities
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
